rubitecan has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aggarwal, BB; Mendoza, J; Pantazis, P; Raju, U; Singh, S | 1 |
1 other study(ies) available for rubitecan and Lymphoma, Large B-Cell, Diffuse
Article | Year |
---|---|
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.
Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Host Cell Factor C1; Humans; Hydrogen Peroxide; I-kappa B Proteins; Interleukin-1; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Octamer Transcription Factor-1; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |